Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 794,867
  • Shares Outstanding, K 52,710
  • Annual Sales, $ 55,510 K
  • Annual Income, $ -346,400 K
  • 36-Month Beta 2.07
  • Price/Sales 14.49
  • Price/Cash Flow N/A
  • Price/Book 3.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -1.73
  • Number of Estimates 5
  • High Estimate -1.57
  • Low Estimate -1.84
  • Prior Year -1.27
  • Growth Rate Est. (year over year) -36.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.50 +31.13%
on 10/31/18
32.01 -52.89%
on 10/17/18
-11.65 (-43.58%)
since 10/12/18
3-Month
11.50 +31.13%
on 10/31/18
37.27 -59.54%
on 08/22/18
-19.47 (-56.35%)
since 08/14/18
52-Week
11.50 +31.13%
on 10/31/18
69.02 -78.15%
on 12/29/17
-50.41 (-76.97%)
since 11/14/17

Most Recent Stories

More News
Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA

PARP inhibitor makers get a boost following priority review for AstraZeneca???s (AZN) label expansion application for Lynparza as a first-line maintenance treatment for ovarian cancer.

AZN : 41.40 (-0.22%)
MRK : 74.09 (-0.70%)
CLVS : 15.08 (-1.18%)
TSRO : 25.99 (-11.27%)
AstraZeneca's Lynparza Gets Priority Review in 1st Line Use

AstraZeneca (AZN) and partner Merck's sNDA looking for label expansion of Lynparza in the first-line setting gets FDA's priority review.

AZN : 41.40 (-0.22%)
MRK : 74.09 (-0.70%)
CLVS : 15.08 (-1.18%)
TSRO : 25.99 (-11.27%)
Recent Analysis Shows Clovis Oncology, Evertec, Etsy, Ring Energy, Ocular Therapeutix, and Destination Maternity Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clovis Oncology, Inc. (NASDAQ:CLVS),...

EVTC : 27.53 (-0.79%)
ETSY : 47.71 (+0.76%)
REI : 7.18 (+0.98%)
CLVS : 15.08 (-1.18%)
DEST : 5.39 (-3.75%)
OCUL : 5.04 (-4.73%)
Clovis Oncology Shares Down 64.9% Since SmarTrend's Sell Call (CLVS)

SmarTrend identified a Downtrend for Clovis Oncology (NASDAQ:CLVS) on July 25th, 2018 at $44.69. In approximately 4 months, Clovis Oncology has returned 64.89% as of today's recent price of $15.69.

CLVS : 15.08 (-1.18%)
Clovis Oncology to Present at the Credit Suisse 27th Annual Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the 27th Annual Healthcare Conference on Wednesday, November...

CLVS : 15.08 (-1.18%)
Shares of Adamas Pharmaceu Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (ADMS , CLVS , CHRS , DVAX , IONS )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

ADMS : 10.86 (-5.73%)
CHRS : 10.96 (-1.62%)
CLVS : 15.08 (-1.18%)
After Yesterday's Rally of 14.06% Shares Could Potentially Pullback

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $14.31 to a high of $16.46. Yesterday, the shares gained 14.1%, which took the trading range above the 3-day high...

CLVS : 15.08 (-1.18%)
TESARO (TSRO) Q3 Earnings Beat, Revenues Miss, Shares Up

TESARO (TSRO) beats estimates for earnings in the third quarter but misses the same on revenues. Zejula sales maintain momentum.

JNJ : 144.25 (-0.30%)
CLVS : 15.08 (-1.18%)
TSRO : 25.99 (-11.27%)
RHHBY : 30.8700 (-0.74%)
Clovis Oncology Has Returned 68.7% Since SmarTrend Recommendation (CLVS)

SmarTrend identified a Downtrend for Clovis Oncology (NASDAQ:CLVS) on July 25th, 2018 at $44.69. In approximately 3 months, Clovis Oncology has returned 68.72% as of today's recent price of $13.98.

CLVS : 15.08 (-1.18%)
Today's Research Reports on Stocks to Watch: Strongbridge Biopharma and Clovis Oncology

NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Strongbridge Biopharma was one of the biggest winners in the biotech arena yesterday after announcing a deal with Denmark's Novo Nordisk. Shares of Clovis...

CLVS : 15.08 (-1.18%)
SBBP : 4.86 (-7.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade CLVS with:

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

2nd Resistance Point 16.47
1st Resistance Point 15.78
Last Price 15.08
1st Support Level 14.37
2nd Support Level 13.65

See More

52-Week High 69.02
Fibonacci 61.8% 47.05
Fibonacci 50% 40.26
Fibonacci 38.2% 33.47
Last Price 15.08
52-Week Low 11.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar